ArticleCell reports2018
The Murine Natural Cytotoxic Receptor NKp46/NCR1 Controls TRAIL Protein Expression in NK Cells and ILC1s.
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in Solid Tumors: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2020Pooled it
- ILC3s as central regulators of mucosal homeostasis and disease pathogenesis (Review).International journal of molecular medicine · 2026Review
- Altered NK cell receptor profiles and immune-inflammatory markers in adolescent major depressive disorder: associations with cognitive impairment.BMC psychiatry · 2026Article
- Role of liver-resident NK cells in liver immunity.Hepatology international · 2025Review
- NKp46 enhances type 1 innate lymphoid cell proliferation and function and anti-acute myeloid leukemia activity.Nature communications · 2025Article
- Advancements in the Study of the Immune Molecule NKp46 in Immune System-related Diseases.Clinical reviews in allergy & immunology · 2024Review
- Natural Killer cells at the frontline in the fight against cancer.Cell death & disease · 2024Review
- The Multifaceted Roles of NK Cells in the Context of Murine Cytomegalovirus and Lymphocytic Choriomeningitis Virus Infections.Immune network · 2024Review
- Article
- NK cell-activating receptor NKp46 does not participate in the development of obesity-induced inflammation and insulin resistance.Molecules and cells · 2024Article
- TRAIL-conjugated liposomes that bind natural killer cells to induce colorectal cancer cell apoptosis.Journal of biomedical materials research. Part A · 2024Article
- Transcriptional regulation of innate lymphoid cells and T cells by aryl hydrocarbon receptor.Frontiers in immunology · 2023Review
- Multi-omics analysis reveals the prognostic and tumor micro-environmental value of lumican in multiple cancer types.Frontiers in molecular biosciences · 2023Article
- Article
- Effect of different cytokines in combination with IL-15 on the expression of activating receptors in NK cells of patients with Behçet's disease.Immunologic research · 2022Article
- Unleashing the power of NK cells in anticancer immunotherapy.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Natural Killer Cells Infiltration in the Joints Exacerbates Collagen-Induced Arthritis.Frontiers in immunology · 2022Article
- Innate lymphoid cells in early tumor development.Frontiers in immunology · 2022Review
- Innate lymphoid cells type 3 in cancer.Frontiers in immunology · 2022Review
- Plasticity of Innate Lymphoid Cells in Cancer.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
Abstract
TRAIL is an apoptosis-inducing ligand constitutively expressed on liver-resident type 1 innate lymphoid cells (ILC1s) and a subset of natural killer (NK) cells, where it contributes to NK cell anti-tumor, anti-viral, and immunoregulatory functions. However, the intrinsic pathways involved in TRAIL expression in ILCs remain unclear. Here, we demonstrate that the murine natural cytotoxic receptor mNKp46/NCR1, expressed on ILC1s and NK cells, controls TRAIL protein expression. Using NKp46-deficient mice, we show that ILC1s lack constitutive expression of TRAIL protein and that NK cells activated in vitro and in vivo fail to upregulate cell surface TRAIL in the absence of NKp46. We show that NKp46 regulates TRAIL expression in a dose-dependent manner and that the reintroduction of NKp46 in mature NK cells deficient for NKp46 is sufficient to restore TRAIL surface expression. These studies uncover a link between NKp46 and TRAIL expression in ILCs with potential implications in pathologies involving NKp46-expressing cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.